The global immunomodulators market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to the rising prevalence of chronic diseases such as cancer, asthma, multiple sclerosis, and allergic conditions. Moreover, the formation or introduction of genesis of new biologics response modifiers presents a key aspect for the market growth.
Immunomodulators are types of medications and agents that ensure a proper function of the immune system by balancing the immune response. Using these drugs, the resistance of the body is enhanced against various infections. These are widely used to avoid the rejection of organs during transplantation. The launch of several novel drugs took place to fight against various diseases that include Crohn’s disease, rheumatoid disease, and others. For instance, SQX770, used for the treatment of recurrent herpes labialis, was a tropical immunomodulator that received positive results in phase 2 trials in 2019. Later, it became the first and only drug to be approved by the US Food and Drug Administration (FDA) to be used for treatment after completing the phase 3 trials with prominent and positive results.
The COVID-19 pandemic had a significant impact on the global immunomodulators market attributed to the increase in the sales of products that are used in the emergency treatment of the COVID patients. Despite the pandemic, a balance has been made between the supply and demand chains by several pharmaceutical companies. These companies are continuously working on enhancing their research & development and improving the management of their supply chain.
Market Trends, Drivers, Restraints, and Opportunities
- For the treatment of Crohn’s disease, the early immunomodulator therapy is widely adopted is a key driver helping the market growth.
- Immunotherapeutic agents are being developed and are under clinical trials due to which the immunomodulators market is expected to register considerable growth.
- Presence of several unmet clinical needs for the treatment of immune disorders including rheumatoid arthritis especially in developing countries is anticipated to fuel the market growth in the coming years.
- Strict & rigid regulations imposed for the approval of immunomodulator antibodies are estimated to act as a restraining point that can hamper the market expansion during the forecast period.
- Ongoing research & development programs in order to provide advanced patient care and increasing candidates of pipeline for the treatment of several diseases are the key opportunities for the market.
Immunomodulators are types of medications and agents that ensure a proper function of the immune system by balancing the immune response. Using these drugs, the resistance of the body is enhanced against various infections. These are widely used to avoid the rejection of organs during transplantation. The launch of several novel drugs took place to fight against various diseases that include Crohn’s disease, rheumatoid disease, and others. For instance, SQX770, used for the treatment of recurrent herpes labialis, was a tropical immunomodulator that received positive results in phase 2 trials in 2019. Later, it became the first and only drug to be approved by the US Food and Drug Administration (FDA) to be used for treatment after completing the phase 3 trials with prominent and positive results.
The COVID-19 pandemic had a significant impact on the global immunomodulators market attributed to the increase in the sales of products that are used in the emergency treatment of the COVID patients. Despite the pandemic, a balance has been made between the supply and demand chains by several pharmaceutical companies. These companies are continuously working on enhancing their research & development and improving the management of their supply chain.
Key Players
- Eli Lily and Co.
- F.Hoffmann-La Roche Ltd.
- Biogen
- Bristol-Myers & Squibb Co.
- Teva Pharmaceuticals Industries Ltd.
- Merck Sharp & Dohme Corp.
- Amgen Inc.
- Novartis AG
Competitive Landscape
Key players competing in the global immunomodulators market are Eli Lily and Co.; F.Hoffmann-La Roche Ltd.; Biogen; Bristol-Myers & Squibb Co.; Teva Pharmaceuticals Industries Ltd.; Merck Sharp & Dohme Corp.; Amgen Inc.; and Novartis AG. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally. Moreover, branded therapies are anticipated to expire, which is expected to provide a profitable growth to the market.
To Get a New Sample Request: https://growthmarketreports.com/request-sample/2357
Contact Us
- Growth Market Reports
- Phone: +1 909 414 1393
- Email: sales@growthmarketreports.com
- Web: https://growthmarketreports.com
